Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics
(PD) of orally administered PLX8394 in patients with advanced solid tumors. An additional
objective is to identify a Recommended Phase 2 (RP2D) for further evaluation in the Extension
Cohorts (Phase IIa portion).
The study objective of the Extension Cohorts (PART 2 portion) is to assess the objective
tumor response and the PK, PD, and safety of PLX8394 when the RP2D is used in patients with
advanced BRAF-mutated cancers.